Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Pseudoprotodioscin
Cat. No.:
OB0225LY-0008
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Pseudoprotodioscin is a secondary metabolite with potential anticancer activity and moderate cytotoxicity.
Synonym:
102115-79-7; beta-D-Glucopyranoside, (3beta,25R)-26-(beta-D-glucopyranosyloxy)furosta-5,20(22)-dien-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1->2)-O-(6-deoxy-alpha-L-mannopyranosyl-(1->4))-
CAS No.:
102115-79-7
Compound CID:
21637110
Formula:
C51H82O21
Formula Weight:
1031.18
Specification
Relative Density:
1.45 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Pseudoprotodioscin can be used to investigate its role in cellular metabolism and anti-inflammatory effects.
Library Information
Targets:
Metabolic enzymes
Receptors:
Fatty acid synthase; MicroRNA
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
a9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
91 mg/mL; 88.2 mM
Solubility:
Soluble in pyridine, methanol, and ethanol.
